Stockscreener 앱 받기
0.3193
4.06%
-0.0135
Quoin Pharmaceuticals Ltd Adr 주식(QNRX)의 최신 뉴스
Stock Performance Spotlight: Quoin Pharmaceuticals Ltd ADR (QNRX) Ends the Day at 0.31, Down by -2.06 - The Dwinnex
Should You Expect Quoin Pharmaceuticals Ltd ADR (NASDAQ:QNRX) To Recover From Its 9.68% Gain From Highs? - Marketing Sentinel
Now Is The Time To Build A Position In Health In Tech Inc (NASDAQ:HIT) - Marketing Sentinel
After A Decline Of -818.6% From The High, Can Evaxion Biotech A/S ADR (NASDAQ: EVAX) Recover Quickly? - Marketing Sentinel
BTC Digital Ltd (NASDAQ: BTCT): Can A Stock Be Up 21.97% YTD, And Still Be A Loser - Marketing Sentinel
ScanTech AI Systems Inc (NASDAQ: STAI) Gain Of 9.66% Compared To 52-Week Low; YTD Fall -84.49% – What Should You Do Now? – Marketing Sentinel - Marketing Sentinel
Now Is The Time To Build A Position In SolarBank Corporation (NASDAQ:SUUN) - Marketing Sentinel
Aurora Mobile Ltd ADR (NASDAQ: JG) Stock Gained 83.28% Over A Month – Any Room To Run? - Marketing Sentinel
Now Is The Time To Build A Position In Atyr Pharma Inc (NASDAQ:ATYR) - Marketing Sentinel
Berry Global Group Inc [BERY] Records 200-Day SMA of $64.89 - Knox Daily
Quoin Pharmaceuticals Ltd ADR [QNRX] stock for 250,000 USD was acquired by Carter Denise P. - Knox Daily
INVZ Shares Experience Surge in Value - Knox Daily
Jefferies Financial Group Inc [JEF] Shares Rise 1.55 % on Thursday - Knox Daily
DHT Holdings Inc [DHT] Shares Jump Approximately 9.62% Over the Year - Knox Daily
Now Is The Time To Build A Position In American Battery Technology Company (NASDAQ:ABAT) - Marketing Sentinel
After Jumping 10.61% During The Past Week, Should You Still Buy Recursion Pharmaceuticals Inc (NASDAQ: RXRX)? - Marketing Sentinel
Beyond Inc (NYSE: BYON) Has Succeeded In Generating Interest In 2025, The Stock Is Up 87.02% Year-To-Date - Marketing Sentinel
Orangekloud Technology Inc (NASDAQ: ORKT) Up 58.11% From 52-Week Low; YTD Falls -50.99% – Here’s What To Do Now – Marketing Sentinel - Marketing Sentinel
Market cap of Captivision Inc [CAPT] reaches 33.99M – now what? - The DBT News
Citigroup lifts StoneCo Ltd [STNE] price estimate. Who else is bullish? - The DBT News
PDD Holdings Inc ADR (NASDAQ: PDD): How To Buy And When To Buy And Its Performance & Trends - Marketing Sentinel
Quoin Pharmaceuticals launches Netherton awareness campaign - Investing.com India
Understanding QNRX’s financial ratios: A beginner’s guide - US Post News
An Overview of Castellum Inc (AMEX: CTM)’s Stock Performance and Outlook - Marketing Sentinel
Let’s Jump Into The SolarBank Corporation (NASDAQ: SUUN) Stock Forecast - Marketing Sentinel
Why Should You Invest In Castellum Inc (AMEX: CTM)? - Marketing Sentinel
Graphjet Technology (NASDAQ:GTI) Stock Plunged -64.80% So Far In 2025, What Analysts Expect Next? - Marketing Sentinel
Earnings call transcript: Quoin Pharmaceuticals Q4 2023 sees stock volatility - MSN
Why Acquire Shares Of Castellum Inc (CTM)? - Marketing Sentinel
Syros Pharmaceuticals Inc (NASDAQ: SYRS) Fell -2280.95%, Predicting What To Expect In The Near Future - Marketing Sentinel
Sobr Safe Inc (NASDAQ: SOBR) Fall -93.95% In Six Months, Here’s What We Should Expect Now - Marketing Sentinel
Future Prospects And Stock Pricing Of DatChat Inc (NASDAQ: DATS) - Marketing Sentinel
Future Outlook And Stock Price Performance For Zeo Energy Corp (NASDAQ: ZEO) - Marketing Sentinel
Future Outlook And Stock Price Performance For Evaxion Biotech A/S ADR (NASDAQ: EVAX) - Marketing Sentinel
Now Is The Time To Build A Position In Pony AI Inc. ADR (NASDAQ:PONY) - Marketing Sentinel
Now Is The Time To Build A Position In NewGenIvf Group Ltd (NASDAQ:NIVF) - Marketing Sentinel
Now Is The Time To Build A Position In MGO Global Inc (NASDAQ:MGOL) - Marketing Sentinel
Now Is The Time To Build A Position In XORTX Therapeutics Inc (NASDAQ:XRTX) - Marketing Sentinel
Quoin reports progress in pediatric skin disorder study - Investing.com
T2 Biosystems Inc (NASDAQ:TTOO) Drops -8.76%, But Further Rally Could Be Imminent - Marketing Sentinel
Now Is The Time To Build A Position In Quoin Pharmaceuticals Ltd ADR (NASDAQ:QNRX) - Marketing Sentinel
PRISM MarketView Spotlights Quoin Pharmaceuticals CEO Dr. Michael Myers as Specialty Pharma Shares News of Highly Positive Interim Data in Most Advanced, Comprehensive Netherton Syndrome Trials - GlobeNewswire Inc.
Analysts Are Recommending Greenwave Technology Solutions Inc (GWAV) As A Buy Candidate - Marketing Sentinel
Quoin Pharmaceuticals reports positive trial results for skin treatment - Investing.com
Quoin reports positive results in Netherton Syndrome study - Investing.com
Future Outlook And Stock Price Performance For AgEagle Aerial Systems Inc (AMEX: UAVS) - Marketing Sentinel
Quoin Pharmaceuticals CFO Dunn Gordon buys $54,999 in shares - Investing.com India
Quoin Pharmaceuticals CEO Michael Myers acquires $250,000 in shares By Investing.com - Investing.com South Africa
Quoin Pharmaceuticals director Anthony Culverwell buys $45,000 in shares - Investing.com India
Quoin Pharmaceuticals COO Denise Carter buys $250,000 in shares - Investing.com India
Quoin Pharmaceuticals COO Denise Carter buys $250,000 in shares By Investing.com - Investing.com South Africa
Quoin Pharmaceuticals director Anthony Culverwell buys $45,000 in shares By Investing.com - Investing.com South Africa
Quoin Pharmaceuticals CFO Dunn Gordon buys $54,999 in shares By Investing.com - Investing.com South Africa
Quoin Pharmaceuticals sets terms for public offering - Investing.com
Quoin Pharmaceuticals advances Netherton Syndrome study - Investing.com India
Quoin Pharmaceuticals amends shareholder rights, adjusts executive compensation - Investing.com India
Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2024 Financial Results - Yahoo Finance
Quoin Pharmaceuticals advances Netherton syndrome treatment trial - Investing.com
Quoin Pharmaceuticals granted extension to meet Nasdaq listing - Investing.com India
Quoin Pharmaceuticals expands UK clinical trials for rare disease - Investing.com
0.27%
3.05%
자본화:
|
볼륨(24시간):